Skip to content

Adaptive Biotechnologies ADPT Balance Sheet Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$77.58M+10.1%$70.5M+28.1%$55.03M+27.5%$43.16M-14.8%$50.65M+5.7%
$140.75M-10.1%$156.49M-0.8%$157.74M+2.0%$154.71M+8.4%$142.78M-18.1%
$2.71M+0.7%$2.69M0.0%$2.69M-1.1%$2.72M+0.3%$2.71M-6.4%
$48.32M-4.1%$50.37M+12.4%$44.82M+1.2%$44.29M+1.6%$43.58M+4.4%
$11.21M+14.1%$9.82M-1.1%$9.93M+18.2%$8.4M-3.2%$8.68M+2.9%
$13.95M+7.2%$13.02M-6.4%$13.91M+23.2%$11.3M+4.6%$10.8M-4.3%
$291.81M-2.8%$300.19M+6.7%$281.44M+7.5%$261.86M+2.1%$256.49M-9.6%
$30.77M-9.8%$34.11M-9.0%$37.5M-8.7%$41.06M-7.6%$44.43M-8.6%
$40.25M-0.9%$40.62M-3.3%$41.99M-3.1%$43.34M-1.5%$44M-3.9%
$118.97M0.0%$118.97M0.0%$118.97M0.0%$118.97M0.0%$118.97M0.0%
$1.31M-24.3%$1.73M-19.9%$2.16M-16.6%$2.58M-14.1%$3.01M-12.2%
$1.24M+2.5%$1.21M-34.3%$1.84M-8.8%$2.01M+6.8%$1.89M-17.6%
$18.89M+42.7%$13.23M+228%$4.04M-83.2%$24.1M-38.8%$39.36M+16.9%
$505.94M-1.3%$512.74M+4.5%$490.61M-1.2%$496.64M-2.8%$510.85M-5.3%
$9.62M+48.7%$6.47M-37.0%$10.27M+48.6%$6.91M+8.6%$6.36M-12.4%
$6.22M-63.4%$16.99M+34.0%$12.68M+30.7%$9.7M+51.3%$6.41M-59.5%
$49.4M+9.3%$45.19M+9.3%$41.34M-25.3%$55.3M+0.9%$54.81M-1.6%
$5.8M+25.0%$4.64M+91.1%$2.43M-20.9%$3.07M+52.7%$2.01M+132%
$8.51M-4.6%$8.92M-5.5%$9.44M-5.2%$9.96M-4.8%$10.46M+2.2%
$807K-19.8%$1.01M-16.6%$1.21M-94.0%$20.03M-19.3%$24.81M-9.0%
$87.01M-3.2%$89.92M+7.9%$83.36M-9.5%$92.14M+4.9%$87.81M-10.4%
$124.75M-1.4%$126.57M-2.2%$129.41M-0.8%$130.5M-0.8%$131.55M-0.7%
$69.12M-1.6%$70.23M-2.9%$72.36M-2.8%$74.41M-2.6%$76.44M-3.4%
$77.63M-1.9%$79.15M-3.2%$81.8M-3.0%$84.37M-2.9%$86.9M-2.8%
$20K0.0%$20K0.0%$20K0.0%$20K0.0%$20K0.0%
$281.7M-2.1%$287.74M+0.5%$286.36M-9.7%$317.1M-1.1%$320.63M-4.8%
$16K+6.7%$15K0.0%$15K0.0%$15K0.0%$15K+7.1%
$1.6B+1.1%$1.58B+1.8%$1.55B+1.0%$1.54B+1.0%$1.52B+1.2%
-$1.38B-1.5%-$1.36B-1.0%-$1.35B+0.7%-$1.36B-1.9%-$1.33B-2.3%
-$28K-111%$253K+19.9%$211K+189%$73K-45.5%$134K-19.3%
$7.9M+27.3%$6.21M+3,511%-$182K-0.6%-$181K+10.4%-$202K+9.8%
$216.34M-1.1%$218.79M+7.0%$204.44M+13.8%$179.72M-5.6%$190.42M-6.1%
$505.94M-1.3%$512.74M+4.5%$490.61M-1.2%$496.64M-2.8%$510.85M-5.3%
$140.75M-10.1%$156.49M-0.8%$157.74M+2.0%$154.71M+8.4%$142.78M-18.1%
$1.24M+2.5%$1.21M-34.3%$1.84M-8.8%$2.01M+6.8%$1.89M-17.6%
$40.25M-0.9%$40.62M-3.3%$41.99M-3.1%$43.34M-1.5%$44M-3.9%
$18.89M+42.7%$13.23M+228%$4.04M-83.2%$24.1M-38.8%$39.36M+16.9%
$1.31M-24.3%$1.73M-19.9%$2.16M-16.6%$2.58M-14.1%$3.01M-12.2%
$40.25M-0.9%$40.62M-3.3%$41.99M-3.1%$43.34M-1.5%$44M-3.9%
$1.24M+2.5%$1.21M-34.3%$1.84M-8.8%$2.01M+6.8%$1.89M-17.6%
$40.25M-0.9%$40.62M-3.3%$41.99M-3.1%$43.34M-1.5%$44M-3.9%
$1.24M+2.5%$1.21M-34.3%$1.84M-8.8%$2.01M+6.8%$1.89M-17.6%
$6.22M-63.4%$16.99M+34.0%$12.68M+30.7%$9.7M+51.3%$6.41M-59.5%
$807K-19.8%$1.01M-16.6%$1.21M-94.0%$20.03M-19.3%$24.81M-9.0%
$7.47M-3.1%$7.7M+6.9%$7.21M0.0%$7.21M-7.1%$7.76M-4.9%
$7.47M-3.1%$7.7M+6.9%$7.21M0.0%$7.21M-7.1%$7.76M-4.9%
$6.22M-63.4%$16.99M+34.0%$12.68M+30.7%$9.7M+51.3%$6.41M-59.5%
$807K-19.8%$1.01M-16.6%$1.21M-94.0%$20.03M-19.3%$24.81M-9.0%
$807K-19.8%$1.01M-16.6%$1.21M-94.0%$20.03M-19.3%$24.81M-9.0%
$208.18M-1.0%$210.36M-1.5%$213.64M-2.0%$217.94M-1.1%$220.46M-1.0%
$16K+6.7%$15K0.0%$15K0.0%$15K0.0%$15K+7.1%
$7.9M+27.3%$6.21M+3,511%-$182K-0.6%-$181K+10.4%-$202K+9.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Adaptive Biotechnologies's total assets?
Adaptive Biotechnologies (ADPT) holds $505.9M in total assets, down 1.0% year over year.
How much debt does Adaptive Biotechnologies have?
Adaptive Biotechnologies carries $208.2M in total debt against $216.3M of shareholders' equity, a debt-to-equity ratio of 0.96.
How much cash does Adaptive Biotechnologies have?
Adaptive Biotechnologies holds $77.6M in cash and equivalents.
Can Adaptive Biotechnologies cover its short-term obligations?
Its current ratio is 3.35 — current assets exceed current liabilities.
Where does Adaptive Biotechnologies's balance sheet data come from?
Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.